CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.…
Is CRISPR Therapeutics (CRSP) Undervalued As CTX310 Data Meets a Share Price Slide?
CRISPR Therapeutics (NASDAQ: CRSP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 39.10 USD on 20 November 2026, down 25.1% over 52 weeks. Its 52-week range is 38.18 USD to 63.45 USD: the price is 38.4% below the high and 2.4% above the low.
Its market capitalisation is 3.79B USD.
CRISPR Therapeutics reports return on equity of -30.3%.
It holds more cash than debt, a net cash position of 1.49B USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 19 analysts cover the stock, with an average rating of Buy; their mean price target of 85.42 USD is 118.5% above the current price. The next earnings report is expected on 11 February 2027.